LONDON – Novabiotics Ltd. is poised to close a $15 million funding round that will enable it to move its lead antimicrobial peptide product, Novexatin, into a Phase IIb trial in nail fungal infection onchomycosis and to advance its second program, Lynovex, into a Phase IIa trial in cystic fibrosis.
Read More
LONDON – A protein known to coordinate degradation of waste products in the liver is also present in the cells of blood vessels and could play a similar role in protecting the body from chemicals that cause cardiovascular disease, researchers have found.
Read More
Johnson & Johnson, in a sense, is going head to head with itself by pitting its investigational protease inhibitor, TMC435, which it in-licensed from Medivir AB, against telaprevir, the hepatitis C virus (HCV) drug it markets as Incivo in Europe, Latin America, India and several other regions, in a Phase III trial.
Read More
DUNDEE, Scotland – Dundee University is renewing its pharma collaboration in protein phosphorylation and the kinase enzymes that control the central aspect of cellular function for the fourth time, in a £15 million (US$23.5 million) plus fees-for-service deal, which will extend the long-running program until 2016.
Read More
• Cytheris SA, of Paris, said a Phase IIa trial (INSPIRE-2) of CYT107 (recombinant interleukin-7) for reconstitution of CD4 T cells in chronic HIV-1 immunological nonresponder patients showed that the drug expanded those cells in the gut mucosa. The companys said it believes the drug may be able to restore the immune system in chronic HIV infection.
Read More
